Bellicum Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	5yrs

Recente managementupdates

Recent updates

CEO

Bellicum Pharmaceuticals heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Charles Grass	Principal Accounting Officer	2.8yrs	geen gegevens	geen gegevens
Joseph Senesac	Senior Vice President of Technical Operations & Quality	2.1yrs	geen gegevens	geen gegevens
Alan Smith	Chief Scientific Officer	3.7yrs	US$791.68k	geen gegevens

2.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BPXA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stephen Davis	Independent Director	8.6yrs	US$61.39k	0.16% € 1.5k
James Daly	Independent Director	7.8yrs	US$51.99k	0.12% € 1.1k
Jon Stonehouse	Interim Independent Chairman	9.2yrs	US$81.89k	0.19% € 1.8k
Reid Huber	Independent Director	9.3yrs	US$64.88k	0.17% € 1.6k
Daniel Powell	Member of Scientific & Clinical Advisory Board	4.9yrs	geen gegevens	geen gegevens
Marco Davila	Member of Scientific & Clinical Advisory Board	4.9yrs	geen gegevens	geen gegevens
Charles Sentman	Member of Scientific & Clinical Advisory Board	4.9yrs	geen gegevens	geen gegevens
Judith Klimovsky	Independent Director	5.2yrs	US$51.99k	0.12% € 1.2k
Gianpietro Dotti	Member of Scientific & Clinical Advisory Board	4.9yrs	geen gegevens	geen gegevens
Malcom Brenner	Member of Scientific & Clinical Advisory Board	4.9yrs	geen gegevens	geen gegevens
Christopher Klebanoff	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens

5.0yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BPXA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).

Bellicum Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Bellicum Pharmaceuticals, Inc. Announces Board Changes

Bellicum Pharmaceuticals, Inc. Announces Resignation of David Strauss as Senior Director, Corporate Controller, and as the Company’s Principal Accounting Officer, Effective January 22, 2021

Recent updates

Bellicum Pharmaceuticals Files Form 15

The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM).

Nasdaq to Delist the Common Stock of Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from NASDAQ Composite Index

Bellicum Pharmaceuticals Receives Written Notification from Nasdaq Regarding Listing Rule 5550(b)(1)

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer At ASCO GU Cancers Symposium

Bellicum Pharmaceuticals, Inc. Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

Insufficient new directors

Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Bellicum Pharmaceuticals, Inc. Announces Board Changes

Bellicum Regains Compliance with Nasdaq Continued Listing Requirements

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Bellicum Pharmaceuticals, Inc. Provides an Operational Update

Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)

Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020

Bellicum Pharmaceuticals, Inc. Announces First Report Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

New 90-day high: €4.46

Bellicum Pharmaceuticals, Inc. Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell 2000 Dynamic Index

Bellicum Pharmaceuticals, Inc. Announces Resignation of David Strauss as Senior Director, Corporate Controller, and as the Company’s Principal Accounting Officer, Effective January 22, 2021

Bellicum Pharmaceuticals, Inc. Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603

Bellicum Pharmaceuticals, Inc. Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc. to Reduce Staff by 2020

Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019

New 90-day low - €5.55

Earnings released

The University of Texas MD Anderson Cancer Center completed the acquisition of certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM).

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell Microcap Value Index

CEO

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd